NCT01037790: Phase II Trial Of The Cyclin-Dependent Kinase Inhibitor PD 0332991 In Patients With Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients with HER2+ or HR+ & HER2-negative breast cancer, must also have ER+ tumor(s)
Exclusions: Untreated or uncontrolled brain metastases

Comments are closed.

Up ↑